Karyopharm Therapeutics (KPTI) Gross Margin (2019 - 2026)
Karyopharm Therapeutics' (KPTI) quarterly Gross Margin came in at 95.73% in Q4 2025, down 8.0% YoY from 104.05% in Q4 2024, and up 0.55% on a QoQ basis from 95.2% in Q3 2025.
Karyopharm Therapeutics (KPTI) Gross Margin (2019 - 2026) Analysis & Trends
Karyopharm Therapeutics (KPTI) has 6 years of Gross Margin data on file, last reported at 95.73% in Q4 2025.
- Quarterly Gross Margin fell 8.0% year-over-year to 95.73% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 95.97% (down 1.0% YoY) and the FY2025 annual result came in at 96.02%, changed 0.0% from the prior year.
- Gross Margin advanced to 95.73% in Q4 2025, from 95.2% in the prior quarter.
- In the past five years, Gross Margin ranged from a high of 99.41% in Q4 2021 to a low of 94.23% in Q1 2024.
- A 5-year average of 96.57% and a median of 96.72% in 2024 frame the typical range for Gross Margin.
- The widest YoY moves for Gross Margin: up 267 bps in 2022, down 430 bps in 2022.
- Tracing KPTI's Gross Margin over 5 years: stood at 99.41% in 2021, then retreated by 4 bps to 95.11% in 2022, then gained by 2 bps to 96.69% in 2023, then dropped by 1 bps to 95.81% in 2024, then slipped by 0 bps to 95.73% in 2025.
- The last three Gross Margin figures came in at 95.73% (Q4 2025), 95.2% (Q3 2025), and 97.32% (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 85.33% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 91.59% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 90.43% |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 35.86% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 89.76% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 76.90% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 84.20% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 63.27% |
| 10 | Karyopharm Therapeutics | 53.25 Mn | 53.25 Mn | 32.35 Mn | 96.75% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 96.75% |
| Dec 31, 2025 | 95.73% |
| Sep 30, 2025 | 95.20% |
| Jun 30, 2025 | 97.32% |
| Mar 31, 2025 | 95.67% |
| Dec 31, 2024 | 95.81% |
| Sep 30, 2024 | 96.81% |
| Jun 30, 2024 | 96.72% |
| Mar 31, 2024 | 94.23% |
| Dec 31, 2023 | 96.69% |
| Sep 30, 2023 | 97.47% |
| Jun 30, 2023 | 96.82% |
| Mar 31, 2023 | 96.51% |
| Dec 31, 2022 | 95.11% |
| Sep 30, 2022 | 97.29% |
| Jun 30, 2022 | 97.63% |
| Mar 31, 2022 | 97.01% |
| Dec 31, 2021 | 99.41% |
| Sep 30, 2021 | 98.44% |
| Jun 30, 2021 | 94.96% |